Cargando…
3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance
Adverse drugs events (ADEs) detection constitutes a considerable concern in patient safety and public health care. For this reason, it is important to develop methods that improve ADE signal detection in pharmacovigilance databases. Our objective is to apply 3D pharmacophoric similarity models to en...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351525/ https://www.ncbi.nlm.nih.gov/pubmed/25744369 http://dx.doi.org/10.1038/srep08809 |
_version_ | 1782360333914996736 |
---|---|
author | Vilar, Santiago Tatonetti, Nicholas P. Hripcsak, George |
author_facet | Vilar, Santiago Tatonetti, Nicholas P. Hripcsak, George |
author_sort | Vilar, Santiago |
collection | PubMed |
description | Adverse drugs events (ADEs) detection constitutes a considerable concern in patient safety and public health care. For this reason, it is important to develop methods that improve ADE signal detection in pharmacovigilance databases. Our objective is to apply 3D pharmacophoric similarity models to enhance ADE recognition in Offsides, a pharmacovigilance resource with drug-ADE associations extracted from the FDA Adverse Event Reporting System (FAERS). We developed a multi-ADE predictor implementing 3D drug similarity based on a pharmacophoric approach, with an ADE reference standard extracted from the SIDER database. The results showed that the application of our 3D multi-type ADE predictor to the pharmacovigilance data in Offsides improved ADE identification and generated enriched sets of drug-ADE signals. The global ROC curve for the Offsides ADE candidates ranked with the 3D similarity score showed an area of 0.7. The 3D predictor also allows the identification of the most similar drug that causes the ADE under study, which could provide hypotheses about mechanisms of action and ADE etiology. Our method is useful in drug development, screening potential adverse effects in experimental drugs, and in drug safety, applicable to the evaluation of ADE signals selected through pharmacovigilance data mining. |
format | Online Article Text |
id | pubmed-4351525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43515252015-03-10 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance Vilar, Santiago Tatonetti, Nicholas P. Hripcsak, George Sci Rep Article Adverse drugs events (ADEs) detection constitutes a considerable concern in patient safety and public health care. For this reason, it is important to develop methods that improve ADE signal detection in pharmacovigilance databases. Our objective is to apply 3D pharmacophoric similarity models to enhance ADE recognition in Offsides, a pharmacovigilance resource with drug-ADE associations extracted from the FDA Adverse Event Reporting System (FAERS). We developed a multi-ADE predictor implementing 3D drug similarity based on a pharmacophoric approach, with an ADE reference standard extracted from the SIDER database. The results showed that the application of our 3D multi-type ADE predictor to the pharmacovigilance data in Offsides improved ADE identification and generated enriched sets of drug-ADE signals. The global ROC curve for the Offsides ADE candidates ranked with the 3D similarity score showed an area of 0.7. The 3D predictor also allows the identification of the most similar drug that causes the ADE under study, which could provide hypotheses about mechanisms of action and ADE etiology. Our method is useful in drug development, screening potential adverse effects in experimental drugs, and in drug safety, applicable to the evaluation of ADE signals selected through pharmacovigilance data mining. Nature Publishing Group 2015-03-06 /pmc/articles/PMC4351525/ /pubmed/25744369 http://dx.doi.org/10.1038/srep08809 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Vilar, Santiago Tatonetti, Nicholas P. Hripcsak, George 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance |
title | 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance |
title_full | 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance |
title_fullStr | 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance |
title_full_unstemmed | 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance |
title_short | 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance |
title_sort | 3d pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351525/ https://www.ncbi.nlm.nih.gov/pubmed/25744369 http://dx.doi.org/10.1038/srep08809 |
work_keys_str_mv | AT vilarsantiago 3dpharmacophoricsimilarityimprovesmultiadversedrugeventidentificationinpharmacovigilance AT tatonettinicholasp 3dpharmacophoricsimilarityimprovesmultiadversedrugeventidentificationinpharmacovigilance AT hripcsakgeorge 3dpharmacophoricsimilarityimprovesmultiadversedrugeventidentificationinpharmacovigilance |